{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:04Z","timestamp":1794047404343,"version":"4.8.0"},"reference-count":30,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"10","license":[{"start":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T00:00:00Z","timestamp":1649289600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>In order to improve the safety of COVID-19 vaccines, there is an urgent need to unravel the pathogenesis of vaccineinduced immune thrombotic thrombocytopenia (VITT), a severe complication of recombinant adenoviral vector vaccines used to prevent COVID-19, and likely due to anti-platelet factor 4 (PF4) IgG antibodies. In this study, we demonstrated that 1E12, a chimeric anti-PF4 antibody with a human Fc fragment, fully mimics the effects of human VITT antibodies, as it activates platelets to a similar level in the presence of platelet factor 4 (PF4). Incubated with neutrophils, platelets and PF4, 1E12 also strongly induces NETosis, and in a microfluidic model of whole blood thrombosis, it triggers the formation of large platelet\/leukocyte thrombi containing fibrin(ogen). In addition, a deglycosylated form of 1E12 (DG-1E12), which still binds PF4 but no longer interacts with Fc\u03b3 receptors, inhibits platelet, granulocyte and clotting activation induced by human anti-PF4 VITT antibodies. This strongly supports that 1E12 and VITT antibodies recognize overlapping epitopes on PF4. In conclusion, 1E12 is a potentially important tool to study the pathophysiology of VITT, and for establishing mouse models. On the other hand, DG-1E12 may help the development of a new drug that specifically neutralizes the pathogenic effect of autoimmune anti-PF4 antibodies, such as those associated with VITT.<\/jats:p>","DOI":"10.3324\/haematol.2021.280251","type":"journal-article","created":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T03:06:42Z","timestamp":1649300802000},"page":"2445-2453","source":"Crossref","is-referenced-by-count":18,"title":["The deglycosylated form of 1E12 inhibits platelet activation and prothrombotic effects induced by VITT antibodies"],"prefix":"10.3324","volume":"107","author":[{"given":"Caroline","family":"Vayne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghavendra","family":"Palankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Billy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Handtke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Thiele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Cordonnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Pouplard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Greinacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Gruel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Rollin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2022,4,7]]},"reference":[{"key":"40507","doi-asserted-by":"crossref","unstructured":"Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 2021; 384(22):2092-2101.","DOI":"10.1056\/NEJMoa2104840"},{"key":"40508","doi-asserted-by":"crossref","unstructured":"Pavord S, Scully M, Hunt BJ. Clinical features of vaccine-induced immune thrombocytopenia and thrombosis. N Engl J Med. 2021; 385(18):1680-1689.","DOI":"10.1056\/NEJMoa2109908"},{"key":"40509","doi-asserted-by":"crossref","unstructured":"Schultz NH, S\u00f8rvoll IH, Michelsen AE. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 2021; 384(22):2124-2130.","DOI":"10.1056\/NEJMoa2104882"},{"key":"40510","doi-asserted-by":"crossref","unstructured":"Perry RJ, Tamborska A, Singh B. Cerebral venous thrombosis after vaccination against COVID-19 in the UK: a multicentre cohort study. Lancet. 2021; 398(10306):1147-1156.","DOI":"10.1016\/S0140-6736(21)01788-8"},{"key":"40511","doi-asserted-by":"crossref","unstructured":"Scully M, Singh D, Lown R. Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 2021; 384(23):2202-2211.","DOI":"10.1056\/NEJMoa2105385"},{"key":"40512","doi-asserted-by":"crossref","unstructured":"Vayne C, Rollin J, Gruel Y. PF4 Immunoassays in vaccine-induced thrombotic thrombocytopenia. N Engl J Med. 2021; 385(4):376-378.","DOI":"10.1056\/NEJMc2106383"},{"key":"40513","doi-asserted-by":"crossref","unstructured":"Gresele P, Momi S, Marcucci R, Ramundo F, De Stefano V, Tripodi A. Interactions of adenoviruses with platelets and coagulation and the vaccine-induced immune thrombotic thrombocytopenia syndrome. Haematologica. 2021; 106(12):3034-3045.","DOI":"10.3324\/haematol.2021.279289"},{"key":"40514","doi-asserted-by":"crossref","unstructured":"Pomara C, Sessa F, Ciaccio M. Post-mortem findings in vaccine-induced thrombotic thombocytopenia. Haematologica. 2021; 106(8):2291-2293.","DOI":"10.3324\/haematol.2021.279075"},{"key":"40515","doi-asserted-by":"crossref","unstructured":"Althaus K, M\u00f6ller P, Uzun G. Antibody-mediated procoagulant platelets in SARS-CoV-2-vaccination associated immune thrombotic thrombocytopenia. Haematologica. 2021; 106(8):2170-2179.","DOI":"10.3324\/haematol.2021.279000"},{"key":"40516","doi-asserted-by":"crossref","unstructured":"Greinacher A, Selleng K, Palankar R. Insights in ChAdOx1 nCov-19 vaccine-induced immune thrombotic thrombocytopenia (VITT). Blood. 2021; 138(22):2256-2268.","DOI":"10.1182\/blood.2021013231"},{"key":"40517","doi-asserted-by":"crossref","unstructured":"Greinacher A, Selleng K, Warkentin TE. Autoimmune heparin-induced thrombocytopenia. J Thromb Haemost. 2017; 15(11):2099-2114.","DOI":"10.1111\/jth.13813"},{"key":"40518","doi-asserted-by":"crossref","unstructured":"Nguyen TH, Medvedev N, Delcea M, Greinacher A. Anti-platelet factor 4\/polyanion antibodies mediate a new mechanism of autoimmunity. Nat Commun. 2017; 8:14945.","DOI":"10.1038\/ncomms14945"},{"key":"40519","doi-asserted-by":"crossref","unstructured":"Kennedy SB, Bolay F, Kieh M. Phase 2 placebo-controlled trial of two vaccines to prevent Ebola in Liberia. N Engl J Med. 2017; 377(15):1438-1447.","DOI":"10.1056\/NEJMoa1614067"},{"key":"40520","doi-asserted-by":"crossref","unstructured":"Milligan ID, Gibani MM, Sewell R. Safety and immunogenicity of novel Adenovirus type 26- and modified Vaccinia Ankara-vectored Ebola vaccines: a randomized clinical trial. JAMA. 2016; 315(15):1610-1623.","DOI":"10.1001\/jama.2016.4218"},{"key":"40521","doi-asserted-by":"crossref","unstructured":"Vayne C, Nguyen TH, Rollin J. Characterization of new monoclonal PF4-specific antibodies as useful tools for studies on typical and autoimmune heparin-induced thrombocytopenia. Thromb Haemost. 2021; 121(3):322-331.","DOI":"10.1055\/s-0040-1717078"},{"key":"40522","doi-asserted-by":"crossref","unstructured":"Kizlik-Masson C, Vayne C, McKenzie SE. 5B9, a monoclonal antiplatelet factor 4\/heparin IgG with a human Fc fragment that mimics heparin-induced thrombocytopenia antibodies. J Thromb Haemost. 2017; 15(10):2065-2075.","DOI":"10.1111\/jth.13786"},{"key":"40523","doi-asserted-by":"crossref","unstructured":"Handtke S, Wolff M, Zaninetti C. A flow cytometric assay to detect platelet-activating antibodies in VITT after ChAdOx1 nCov-19 vaccination. Blood. 2021; 137(26):3656-3659.","DOI":"10.1182\/blood.2021012064"},{"key":"40524","doi-asserted-by":"crossref","unstructured":"Greinacher A, Selleng K, Palankar R. Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia. Blood. 2021; 138(22):2256-2268.","DOI":"10.1182\/blood.2021013231"},{"key":"40525","doi-asserted-by":"crossref","unstructured":"Holm S, Kared H, Michelsen AE. Immune complexes, innate immunity, and NETosis in ChAdOx1 vaccine-induced thrombocytopenia. Eur Heart J. 2021; 42(39):4064-4072.","DOI":"10.1093\/eurheartj\/ehab506"},{"key":"40526","doi-asserted-by":"crossref","unstructured":"Gollomp K, Kim M, Johnston I. Neutrophil accumulation and NET release contribute to thrombosis in HIT. JCI Insight. 2018; 3(18):e99445.","DOI":"10.1172\/jci.insight.99445"},{"key":"40527","doi-asserted-by":"crossref","unstructured":"Kizlik-Masson C, Deveuve Q, Zhou Y. Cleavage of anti-PF4\/heparin IgG by a bacterial protease and potential benefit in heparin-induced thrombocytopenia. Blood. 2019; 133(22):2427-2435.","DOI":"10.1182\/blood.2019000437"},{"key":"40528","doi-asserted-by":"crossref","unstructured":"Radaev S, Sun PD. Recognition of IgG by Fcgamma receptor. The role of Fc glycosylation and the binding of peptide inhibitors. J Biol Chem. 2001; 276(19):16478-16483.","DOI":"10.1074\/jbc.M100351200"},{"key":"40529","doi-asserted-by":"crossref","unstructured":"Huynh A, Kelton JG, Arnold DM, Daka M, Nazy I. Antibody epitopes in vaccine-induced immune thrombotic thrombocytopaenia. Nature. 2021; 596(7873):565-569.","DOI":"10.1038\/s41586-021-03744-4"},{"key":"40530","doi-asserted-by":"crossref","unstructured":"Singh B, Kanack A, Bayas A. Anti-PF4 VITT antibodies are oligoclonal and variably inhibited by heparin. medRxiv. 2021.","DOI":"10.1101\/2021.09.23.21263047"},{"key":"40531","doi-asserted-by":"crossref","unstructured":"Bourguignon A, Arnold DM, Warkentin TE. Adjunct immune globulin for vaccine-induced immune thrombotic thrombocytopenia. N Engl J Med. 2021; 385(8):720-728.","DOI":"10.1056\/NEJMoa2107051"},{"key":"40532","doi-asserted-by":"crossref","unstructured":"Douxfils J, Vayne C, Pouplard C. Fatal exacerbation of ChadOx1-nCoV-19-induced thrombotic thrombocytopenia syndrome after initial successful therapy with intravenous immunoglobulins - a rational for monitoring immunoglobulin G levels. Haematologica. 2021; 106(12):3249-3252.","DOI":"10.3324\/haematol.2021.279509"},{"key":"40533","doi-asserted-by":"crossref","unstructured":"Bakchoul T, Greinacher A, Sachs UJ. Inhibition of HPA-1a alloantibody-mediated platelet destruction by a deglycosylated anti-HPA-1a monoclonal antibody in mice: toward targeted treatment of fetal-alloimmune thrombocytopenia. Blood. 2013; 122(3):321-327.","DOI":"10.1182\/blood-2012-11-468561"},{"key":"40534","doi-asserted-by":"crossref","unstructured":"Sarkar A, Khandelwal S, Yarovoi S. Fc-modified Kko: a novel therapeutic for heparin-induced thrombocytopenia (HIT), reversing both the thrombocytopenia and thrombosis. Blood. 2021; 138(Suppl 1):S581.","DOI":"10.1182\/blood-2021-146233"},{"key":"40535","doi-asserted-by":"crossref","unstructured":"Greinacher A, Langer F, Schonborn L. Platelet-activating anti-PF4 antibodies mimicking VITT antibodies in an unvaccinated patient with monoclonal gammopathy. Haematologica. 2022; 107(5):1219-1221.","DOI":"10.3324\/haematol.2021.280366"},{"key":"40536","doi-asserted-by":"crossref","unstructured":"Nazy I, Sachs UJ, Arnold DM. Recommendations for the clinical and laboratory diagnosis of VITT against COVID-19: communication from the ISTH SSC Subcommittee on Platelet Immunology. J Thromb Haemost. 2021; 19(6):1585-1588.","DOI":"10.1111\/jth.15341"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2021.280251\/74353","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2021.280251\/74895","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/10599\/74353","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:01:27Z","timestamp":1794045687000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2021.280251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,7]]},"references-count":30,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2021.280251","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4,7]]}}}